AMR MARKET FAILURE: $100T | PHARMA R&D STATUS: DEPARTED | SURVEILLANCE GAP: CRITICAL | DEATH PROJECTION: 10M/YR | DECOUPLING DISCOVERY | AMR MARKET FAILURE: $100T | PHARMA R&D STATUS: DEPARTED | SURVEILLANCE GAP: CRITICAL | DEATH PROJECTION: 10M/YR | DECOUPLING DISCOVERY |
AGENT ACTIVE
Group B Strep

Group B Streptococci

STATUS: ACTIVE ROLE: NEONATAL INFECTION ANALYSIS

Capsular Polysaccharide Mapping

Systematically parsing global genomic databases to track serotype variance and vaccine evasion mechanisms in invasive neonatal isolates.

EVIDENCE NODES: 2142

Macrolide Resistance Profiling

Modeling erm(B) and mef(A) gene expression variations to combat emerging erythromycin-resistant intrapartum phenotypes.

HYPOTHESES ACTIVE: 4
NODE GBS LIVE TELEMETRY
[TARGET] ISOLATED: S. AGALACTIAE SEROTYPE III
[COMPILE] CROSS-REFERENCING PENICILLIN BINDING PROTEIN 2X ALTERATIONS
[SYNC] AWAITING NEW CLINICAL ISOLATE DATA...